[go: up one dir, main page]

PT3580220T - Aminotriazolopiridinas como inibidores de quinase - Google Patents

Aminotriazolopiridinas como inibidores de quinase

Info

Publication number
PT3580220T
PT3580220T PT187074984T PT18707498T PT3580220T PT 3580220 T PT3580220 T PT 3580220T PT 187074984 T PT187074984 T PT 187074984T PT 18707498 T PT18707498 T PT 18707498T PT 3580220 T PT3580220 T PT 3580220T
Authority
PT
Portugal
Prior art keywords
aminotriazolopyridines
kinase inhibitors
kinase
inhibitors
Prior art date
Application number
PT187074984T
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PT3580220T publication Critical patent/PT3580220T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/5025Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT187074984T 2017-02-13 2018-02-12 Aminotriazolopiridinas como inibidores de quinase PT3580220T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762458144P 2017-02-13 2017-02-13

Publications (1)

Publication Number Publication Date
PT3580220T true PT3580220T (pt) 2022-01-03

Family

ID=61283335

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187074984T PT3580220T (pt) 2017-02-13 2018-02-12 Aminotriazolopiridinas como inibidores de quinase

Country Status (25)

Country Link
US (3) US10913738B2 (pt)
EP (1) EP3580220B1 (pt)
JP (1) JP7097373B2 (pt)
KR (1) KR102549952B1 (pt)
CN (1) CN110520423B (pt)
AU (1) AU2018217488B2 (pt)
BR (1) BR112019016635A2 (pt)
CA (1) CA3053484A1 (pt)
CY (1) CY1124978T1 (pt)
DK (1) DK3580220T3 (pt)
EA (1) EA039808B1 (pt)
ES (1) ES2902676T3 (pt)
HR (1) HRP20212000T1 (pt)
HU (1) HUE057801T2 (pt)
IL (1) IL268614B (pt)
LT (1) LT3580220T (pt)
MA (1) MA47460A (pt)
MX (1) MX378515B (pt)
PL (1) PL3580220T3 (pt)
PT (1) PT3580220T (pt)
RS (1) RS62801B1 (pt)
SG (1) SG11201907335UA (pt)
SI (1) SI3580220T1 (pt)
SM (1) SMT202200001T1 (pt)
WO (1) WO2018148626A1 (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA47460A (fr) * 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
BR112020007557A2 (pt) * 2017-10-30 2020-09-24 Bristol-Myers Squibb Company inibidores de aminoimidazopiridazinas como inibidores de cinase
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
CN112689633B (zh) 2018-07-09 2025-01-24 利伯研究所公司 用于抑制Nav1.8的吡啶甲酰胺化合物
CN112689629B (zh) 2018-07-09 2024-04-23 利伯研究所公司 用于抑制Nav1.8的哒嗪化合物
SG11202102406XA (en) * 2018-09-13 2021-04-29 Bristol Myers Squibb Co Indazole carboxamides as kinase inhibitors
US12172975B2 (en) 2018-09-13 2024-12-24 Bristol-Myers Squibb Company 1H-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (RIPK1)
KR102769633B1 (ko) * 2019-01-25 2025-02-19 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 아실아미노 가교된 헤테로사이클릭 화합물, 및 이의 조성물 및 응용
CN113508109B (zh) * 2019-03-22 2023-02-10 劲方医药科技(上海)有限公司 取代的杂环酰胺类化合物,其制法与医药上的用途
JP7441477B2 (ja) * 2020-02-13 2024-03-01 ▲勁▼方医▲薬▼科技(上海)有限公司 ジヒドロナフチリドン系化合物、その調製方法及び医薬への使用
CN114230565B (zh) 2020-09-09 2023-10-27 成都奥睿药业有限公司 5-取代吲哚3-酰胺衍生物及其制备方法和用途
CN114262322A (zh) 2020-09-16 2022-04-01 中国科学院上海有机化学研究所 一类细胞程序性坏死抑制剂及其制备方法和用途
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
KR20240135076A (ko) 2021-08-10 2024-09-10 애브비 인코포레이티드 니코틴아미드 ripk1 억제제
CN118647617A (zh) 2022-03-16 2024-09-13 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
CN116574053A (zh) * 2022-06-21 2023-08-11 中国药科大学 Ripk1激酶靶点抑制剂及其医药用途
WO2024146945A1 (en) 2023-01-07 2024-07-11 Syngenta Crop Protection Ag Novel carboxamide and sulfonamide pesticidal compounds

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005260031B2 (en) * 2004-06-25 2008-10-09 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
US8008481B2 (en) 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
ES2320955B1 (es) 2007-03-02 2010-03-16 Laboratorios Almirall S.A. Nuevos derivados de 3-((1,2,4)triazolo(4,3-a)piridin-7-il)benzamida.
CA2706578A1 (en) 2007-11-27 2009-06-04 Cellzome Limited Amino triazoles as pi3k inhibitors
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
WO2010057877A1 (en) 2008-11-18 2010-05-27 Cellzome Limited 7-pyridinyl- or phenyl- substituted triazolo [1, 5 -a] pyridines as pi3k inhibitors
EP2393813B1 (en) 2009-02-04 2013-07-31 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11 ß-hydroxysteroid dehydrogenase 1 useful for the treatment of diseases related to elevated level of cortisol
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
AU2014280395A1 (en) 2013-06-10 2015-12-17 Bayer Pharma Aktiengesellschaft Novel compounds for the treatment of cancer
JP2017524028A (ja) 2014-08-21 2017-08-24 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited 薬剤としてのrip1キナーゼ阻害剤である複素環式アミド
JP6763396B2 (ja) * 2015-11-05 2020-09-30 住友化学株式会社 縮合複素環化合物
WO2018017435A1 (en) 2016-07-22 2018-01-25 Accro Bioscience Inc. Heteroaryl compounds as inhibitors of necrosis, composition and application thereof
US11161843B2 (en) 2017-01-24 2021-11-02 Sumitomo Chemical Company, Limited Fused heterocyclic compound and composition containing same
MA47460A (fr) * 2017-02-13 2019-12-18 Bristol Myers Squibb Co Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
BR112020007557A2 (pt) 2017-10-30 2020-09-24 Bristol-Myers Squibb Company inibidores de aminoimidazopiridazinas como inibidores de cinase
SG11202007035YA (en) 2018-01-26 2020-08-28 Bristol Myers Squibb Co Aminopyrrolotriazines as kinase inhibitors
AR123793A1 (es) * 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas

Also Published As

Publication number Publication date
US20190389859A1 (en) 2019-12-26
JP2020507582A (ja) 2020-03-12
HUE057801T2 (hu) 2022-06-28
JP7097373B2 (ja) 2022-07-07
US12157733B2 (en) 2024-12-03
IL268614B (en) 2021-12-01
PL3580220T3 (pl) 2022-02-07
EP3580220A1 (en) 2019-12-18
SG11201907335UA (en) 2019-09-27
CY1124978T1 (el) 2023-01-05
EA201991915A1 (ru) 2019-12-30
EA039808B1 (ru) 2022-03-16
EP3580220B1 (en) 2021-11-17
CA3053484A1 (en) 2018-08-16
KR20190117006A (ko) 2019-10-15
RS62801B1 (sr) 2022-02-28
SMT202200001T1 (it) 2022-03-21
SI3580220T1 (sl) 2022-01-31
ES2902676T3 (es) 2022-03-29
AU2018217488B2 (en) 2021-09-23
MX2019009555A (es) 2019-10-02
WO2018148626A1 (en) 2018-08-16
DK3580220T3 (da) 2022-01-10
MA47460A (fr) 2019-12-18
US20220315580A1 (en) 2022-10-06
IL268614A (en) 2019-10-31
HRP20212000T1 (hr) 2022-04-01
AU2018217488A1 (en) 2019-10-03
BR112019016635A2 (pt) 2020-04-07
CN110520423B (zh) 2022-08-23
CN110520423A (zh) 2019-11-29
MX378515B (es) 2025-03-11
US10913738B2 (en) 2021-02-09
LT3580220T (lt) 2021-12-27
KR102549952B1 (ko) 2023-06-29
US20250074909A1 (en) 2025-03-06

Similar Documents

Publication Publication Date Title
FR24C1016I1 (fr) Inhibiteurs de ret
CY2024003I1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
PT3580220T (pt) Aminotriazolopiridinas como inibidores de quinase
EP3347018A4 (en) HEMMER OF CYCLINE-DEPENDENT KINASES
DK3303334T3 (da) Tyrosinkinasehæmmere
EP3247692A4 (en) INHIBITORS OF TRKA KINASE
BR112017025542A2 (pt) compostos de naftiridina como inibidores de quinase jak
CL2016002502A1 (es) Inhibidores de biaril cinasa
PT3209656T (pt) Compostos de indol carboxamida úteis como inibidores de quinase
MA42242A (fr) Inhibiteurs de la tyrosine kinase
DK3442972T3 (da) Bromdomænehæmmere
PT3105226T (pt) Ciclopropilaminas como inibidores de lsd1
EP3313828A4 (en) METALLO-BETA-Lactamase INHIBITORS
DK3681884T3 (da) Rad51-inhibitorer
DK3571192T3 (da) Jak1-selektive inhibitorer
CL2016002638A1 (es) Nuevos inhibidores de la nitrificación
LT3704118T (lt) Aminoimidazopiridazinai, kaip kinazės inhibitoriai
IL269063B (en) Pyrimidopyrimidinones used as wee-1 kinase inhibitors
EP3394068A4 (en) TDO2 INHIBITORS
MA43367A (fr) Inhibiteurs de métallo-bêta-lactamases
DK3630744T3 (da) Pyrazol-magl-inhibitorer
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
EP3309163A4 (en) SUBSTITUTED DIHYDROPYRROLO PYRAZOL DERIVATIVE
EP3303283A4 (en) Fto inhibitors
EP3600301A4 (en) KDM4 INHIBITORS